nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP1A1—Clobetasol propionate—psoriasis	0.0888	0.167	CbGbCtD
Bortezomib—CYP1A1—Methoxsalen—psoriasis	0.0466	0.0879	CbGbCtD
Bortezomib—CYP2C8—Tazarotene—psoriasis	0.0418	0.0788	CbGbCtD
Bortezomib—CYP1A2—Clobetasol propionate—psoriasis	0.0396	0.0748	CbGbCtD
Bortezomib—CYP1A1—Cholecalciferol—psoriasis	0.0309	0.0583	CbGbCtD
Bortezomib—CYP1A2—Methoxsalen—psoriasis	0.0208	0.0393	CbGbCtD
Bortezomib—CYP2D6—Hydroxyurea—psoriasis	0.0188	0.0354	CbGbCtD
Bortezomib—CYP2C8—Cholecalciferol—psoriasis	0.0178	0.0336	CbGbCtD
Bortezomib—CYP2C8—Mycophenolate mofetil—psoriasis	0.0155	0.0291	CbGbCtD
Bortezomib—CYP2C19—Cholecalciferol—psoriasis	0.015	0.0282	CbGbCtD
Bortezomib—CYP3A4—Calcitriol—psoriasis	0.014	0.0265	CbGbCtD
Bortezomib—CYP1A1—Dexamethasone—psoriasis	0.0134	0.0252	CbGbCtD
Bortezomib—CYP2C9—Cholecalciferol—psoriasis	0.0124	0.0234	CbGbCtD
Bortezomib—CYP2C8—Hydrocortisone—psoriasis	0.0124	0.0234	CbGbCtD
Bortezomib—CYP2C8—Cyclosporine—psoriasis	0.0117	0.0221	CbGbCtD
Bortezomib—CYP2D6—Cholecalciferol—psoriasis	0.0114	0.0214	CbGbCtD
Bortezomib—CYP3A4—Methoxsalen—psoriasis	0.0109	0.0206	CbGbCtD
Bortezomib—CYP2C19—Prednisone—psoriasis	0.0104	0.0195	CbGbCtD
Bortezomib—CYP2C19—Cyclosporine—psoriasis	0.00982	0.0185	CbGbCtD
Bortezomib—CYP2C9—Cyclosporine—psoriasis	0.00817	0.0154	CbGbCtD
Bortezomib—CYP2C8—Dexamethasone—psoriasis	0.00771	0.0145	CbGbCtD
Bortezomib—CYP2D6—Cyclosporine—psoriasis	0.00747	0.0141	CbGbCtD
Bortezomib—CYP3A4—Cholecalciferol—psoriasis	0.00723	0.0136	CbGbCtD
Bortezomib—CYP2C19—Dexamethasone—psoriasis	0.00647	0.0122	CbGbCtD
Bortezomib—CYP3A4—Triamcinolone—psoriasis	0.00627	0.0118	CbGbCtD
Bortezomib—CYP3A4—Mycophenolate mofetil—psoriasis	0.00627	0.0118	CbGbCtD
Bortezomib—CYP2C9—Dexamethasone—psoriasis	0.00538	0.0101	CbGbCtD
Bortezomib—CYP3A4—Betamethasone—psoriasis	0.00538	0.0101	CbGbCtD
Bortezomib—PSMB2—skin epidermis—psoriasis	0.00534	0.159	CbGeAlD
Bortezomib—CYP3A4—Prednisolone—psoriasis	0.00531	0.01	CbGbCtD
Bortezomib—CYP3A4—Hydrocortisone—psoriasis	0.00503	0.00949	CbGbCtD
Bortezomib—CYP3A4—Prednisone—psoriasis	0.00501	0.00945	CbGbCtD
Bortezomib—CYP2D6—Dexamethasone—psoriasis	0.00492	0.00928	CbGbCtD
Bortezomib—CYP3A4—Cyclosporine—psoriasis	0.00475	0.00896	CbGbCtD
Bortezomib—CYP3A4—Dexamethasone—psoriasis	0.00313	0.0059	CbGbCtD
Bortezomib—CTSG—skin of body—psoriasis	0.0031	0.0924	CbGeAlD
Bortezomib—PSMA1—skin of body—psoriasis	0.00297	0.0887	CbGeAlD
Bortezomib—CTSG—tendon—psoriasis	0.00236	0.0703	CbGeAlD
Bortezomib—PSMD2—skin of body—psoriasis	0.00221	0.0659	CbGeAlD
Bortezomib—PSMD1—tendon—psoriasis	0.0019	0.0567	CbGeAlD
Bortezomib—PSMB1—skin of body—psoriasis	0.0017	0.0506	CbGeAlD
Bortezomib—PSMD2—tendon—psoriasis	0.00168	0.0502	CbGeAlD
Bortezomib—PSMB8—tendon—psoriasis	0.00167	0.0499	CbGeAlD
Bortezomib—PSMB2—skin of body—psoriasis	0.00166	0.0494	CbGeAlD
Bortezomib—CYP1A1—skin epidermis—psoriasis	0.00157	0.0469	CbGeAlD
Bortezomib—PSMB5—tendon—psoriasis	0.00148	0.0441	CbGeAlD
Bortezomib—PSMB1—tendon—psoriasis	0.00129	0.0385	CbGeAlD
Bortezomib—PSMB2—tendon—psoriasis	0.00126	0.0376	CbGeAlD
Bortezomib—SLC31A1—tendon—psoriasis	0.00109	0.0325	CbGeAlD
Bortezomib—PTGS1—endothelium—psoriasis	0.001	0.0299	CbGeAlD
Bortezomib—CYP1A1—skin of body—psoriasis	0.000487	0.0145	CbGeAlD
Bortezomib—Nateglinide—PPARG—psoriasis	0.000485	1	CrCbGaD
Bortezomib—PTGS1—skin of body—psoriasis	0.000428	0.0128	CbGeAlD
Bortezomib—PTGS1—tendon—psoriasis	0.000326	0.00971	CbGeAlD
Bortezomib—PSMD2—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.000274	0.0482	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Fluocinonide—psoriasis	0.00022	0.0386	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Beclomethasone—psoriasis	0.00022	0.0386	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.000214	0.0375	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Clobetasol propionate—psoriasis	0.000198	0.0347	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Beclomethasone—psoriasis	0.000158	0.0278	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Fluocinonide—psoriasis	0.000158	0.0278	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Fluocinolone Acetonide—psoriasis	0.000154	0.027	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Clobetasol propionate—psoriasis	0.00015	0.0264	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Clobetasol propionate—psoriasis	0.000139	0.0244	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Clobetasol propionate—psoriasis	0.000139	0.0244	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Fluocinonide—psoriasis	0.000121	0.0211	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Beclomethasone—psoriasis	0.000121	0.0211	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Fluocinolone Acetonide—psoriasis	0.000117	0.0206	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Fluocinonide—psoriasis	0.000111	0.0195	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Beclomethasone—psoriasis	0.000111	0.0195	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Fluocinonide—psoriasis	0.000111	0.0195	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Beclomethasone—psoriasis	0.000111	0.0195	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Fluocinolone Acetonide—psoriasis	0.000108	0.019	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Fluocinolone Acetonide—psoriasis	0.000108	0.019	CbGdCrCtD
Bortezomib—PSMB8—Medrysone—Hydrocortisone—psoriasis	0.000107	0.0188	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Betamethasone—psoriasis	0.0001	0.0176	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Dexamethasone—psoriasis	0.0001	0.0176	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Triamcinolone—psoriasis	9.79e-05	0.0172	CbGdCrCtD
Bortezomib—PSMB8—Medrysone—Prednisolone—psoriasis	9.02e-05	0.0158	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Clobetasol propionate—psoriasis	8.07e-05	0.0142	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Clobetasol propionate—psoriasis	8.07e-05	0.0142	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Hydrocortisone—psoriasis	7.77e-05	0.0136	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Dexamethasone—psoriasis	7.21e-05	0.0127	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Betamethasone—psoriasis	7.21e-05	0.0127	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Triamcinolone—psoriasis	7.05e-05	0.0124	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Prednisone—psoriasis	6.69e-05	0.0117	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Prednisolone—psoriasis	6.53e-05	0.0115	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Fluocinonide—psoriasis	6.46e-05	0.0113	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Beclomethasone—psoriasis	6.46e-05	0.0113	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Fluocinonide—psoriasis	6.46e-05	0.0113	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Beclomethasone—psoriasis	6.46e-05	0.0113	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Fluocinolone Acetonide—psoriasis	6.28e-05	0.011	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Fluocinolone Acetonide—psoriasis	6.28e-05	0.011	CbGdCrCtD
Bortezomib—PSMB8—Testosterone Propionate—Hydrocortisone—psoriasis	5.98e-05	0.0105	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Dexamethasone—psoriasis	5.49e-05	0.00964	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Betamethasone—psoriasis	5.49e-05	0.00964	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Hydrocortisone—psoriasis	5.47e-05	0.00959	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Hydrocortisone—psoriasis	5.47e-05	0.00959	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Triamcinolone—psoriasis	5.37e-05	0.00942	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Prednisone—psoriasis	5.09e-05	0.00894	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Dexamethasone—psoriasis	5.08e-05	0.00891	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Betamethasone—psoriasis	5.08e-05	0.00891	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Prednisolone—psoriasis	4.97e-05	0.00873	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Triamcinolone—psoriasis	4.96e-05	0.00871	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Triamcinolone—psoriasis	4.96e-05	0.00871	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Prednisone—psoriasis	4.71e-05	0.00826	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Prednisone—psoriasis	4.71e-05	0.00826	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Prednisolone—psoriasis	4.6e-05	0.00807	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Prednisolone—psoriasis	4.6e-05	0.00807	CbGdCrCtD
Bortezomib—PSMB8—Norethindrone—Hydrocortisone—psoriasis	4.48e-05	0.00786	CbGdCrCtD
Bortezomib—PSMB8—Levonorgestrel—Hydrocortisone—psoriasis	3.56e-05	0.00625	CbGdCrCtD
Bortezomib—Haemoglobin—Methotrexate—psoriasis	3.45e-05	0.000127	CcSEcCtD
Bortezomib—Rash—Mycophenolic acid—psoriasis	3.44e-05	0.000127	CcSEcCtD
Bortezomib—Dermatitis—Mycophenolic acid—psoriasis	3.43e-05	0.000126	CcSEcCtD
Bortezomib—Pain—Prednisolone—psoriasis	3.43e-05	0.000126	CcSEcCtD
Bortezomib—Haemorrhage—Methotrexate—psoriasis	3.43e-05	0.000126	CcSEcCtD
Bortezomib—Hepatitis—Methotrexate—psoriasis	3.43e-05	0.000126	CcSEcCtD
Bortezomib—Urticaria—Mycophenolate mofetil—psoriasis	3.42e-05	0.000126	CcSEcCtD
Bortezomib—Headache—Mycophenolic acid—psoriasis	3.41e-05	0.000126	CcSEcCtD
Bortezomib—Decreased appetite—Hydrocortisone—psoriasis	3.41e-05	0.000125	CcSEcCtD
Bortezomib—Abdominal pain—Mycophenolate mofetil—psoriasis	3.4e-05	0.000125	CcSEcCtD
Bortezomib—Body temperature increased—Mycophenolate mofetil—psoriasis	3.4e-05	0.000125	CcSEcCtD
Bortezomib—Urinary tract disorder—Methotrexate—psoriasis	3.39e-05	0.000125	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Hydrocortisone—psoriasis	3.38e-05	0.000125	CcSEcCtD
Bortezomib—Fatigue—Hydrocortisone—psoriasis	3.38e-05	0.000124	CcSEcCtD
Bortezomib—Vision blurred—Prednisone—psoriasis	3.37e-05	0.000124	CcSEcCtD
Bortezomib—Urethral disorder—Methotrexate—psoriasis	3.36e-05	0.000124	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Triamcinolone—psoriasis	3.36e-05	0.000124	CcSEcCtD
Bortezomib—Pain—Hydrocortisone—psoriasis	3.35e-05	0.000123	CcSEcCtD
Bortezomib—Anaphylactic shock—Dexamethasone—psoriasis	3.35e-05	0.000123	CcSEcCtD
Bortezomib—Anaphylactic shock—Betamethasone—psoriasis	3.35e-05	0.000123	CcSEcCtD
Bortezomib—Oedema—Betamethasone—psoriasis	3.35e-05	0.000123	CcSEcCtD
Bortezomib—Oedema—Dexamethasone—psoriasis	3.35e-05	0.000123	CcSEcCtD
Bortezomib—Insomnia—Triamcinolone—psoriasis	3.34e-05	0.000123	CcSEcCtD
Bortezomib—Infection—Dexamethasone—psoriasis	3.33e-05	0.000122	CcSEcCtD
Bortezomib—Infection—Betamethasone—psoriasis	3.33e-05	0.000122	CcSEcCtD
Bortezomib—Ill-defined disorder—Prednisone—psoriasis	3.32e-05	0.000122	CcSEcCtD
Bortezomib—Paraesthesia—Triamcinolone—psoriasis	3.31e-05	0.000122	CcSEcCtD
Bortezomib—Feeling abnormal—Prednisolone—psoriasis	3.31e-05	0.000122	CcSEcCtD
Bortezomib—Visual impairment—Methotrexate—psoriasis	3.31e-05	0.000122	CcSEcCtD
Bortezomib—Anaemia—Prednisone—psoriasis	3.3e-05	0.000122	CcSEcCtD
Bortezomib—Shock—Dexamethasone—psoriasis	3.29e-05	0.000121	CcSEcCtD
Bortezomib—Shock—Betamethasone—psoriasis	3.29e-05	0.000121	CcSEcCtD
Bortezomib—Dyspnoea—Triamcinolone—psoriasis	3.29e-05	0.000121	CcSEcCtD
Bortezomib—Nervous system disorder—Dexamethasone—psoriasis	3.28e-05	0.000121	CcSEcCtD
Bortezomib—Nervous system disorder—Betamethasone—psoriasis	3.28e-05	0.000121	CcSEcCtD
Bortezomib—Agitation—Prednisone—psoriasis	3.28e-05	0.000121	CcSEcCtD
Bortezomib—Thrombocytopenia—Dexamethasone—psoriasis	3.28e-05	0.000121	CcSEcCtD
Bortezomib—Thrombocytopenia—Betamethasone—psoriasis	3.28e-05	0.000121	CcSEcCtD
Bortezomib—Tachycardia—Betamethasone—psoriasis	3.27e-05	0.00012	CcSEcCtD
Bortezomib—Tachycardia—Dexamethasone—psoriasis	3.27e-05	0.00012	CcSEcCtD
Bortezomib—Angioedema—Prednisone—psoriasis	3.26e-05	0.00012	CcSEcCtD
Bortezomib—Hypersensitivity—Cyclosporine—psoriasis	3.25e-05	0.00012	CcSEcCtD
Bortezomib—Dyspepsia—Triamcinolone—psoriasis	3.25e-05	0.00012	CcSEcCtD
Bortezomib—Erythema multiforme—Methotrexate—psoriasis	3.24e-05	0.000119	CcSEcCtD
Bortezomib—Nausea—Mycophenolic acid—psoriasis	3.24e-05	0.000119	CcSEcCtD
Bortezomib—Hyperhidrosis—Dexamethasone—psoriasis	3.24e-05	0.000119	CcSEcCtD
Bortezomib—Hyperhidrosis—Betamethasone—psoriasis	3.24e-05	0.000119	CcSEcCtD
Bortezomib—Feeling abnormal—Hydrocortisone—psoriasis	3.23e-05	0.000119	CcSEcCtD
Bortezomib—Malaise—Prednisone—psoriasis	3.22e-05	0.000119	CcSEcCtD
Bortezomib—Vertigo—Prednisone—psoriasis	3.21e-05	0.000118	CcSEcCtD
Bortezomib—Eye disorder—Methotrexate—psoriasis	3.21e-05	0.000118	CcSEcCtD
Bortezomib—Gastrointestinal pain—Hydrocortisone—psoriasis	3.2e-05	0.000118	CcSEcCtD
Bortezomib—Syncope—Prednisone—psoriasis	3.2e-05	0.000118	CcSEcCtD
Bortezomib—Tinnitus—Methotrexate—psoriasis	3.2e-05	0.000118	CcSEcCtD
Bortezomib—Anorexia—Betamethasone—psoriasis	3.19e-05	0.000117	CcSEcCtD
Bortezomib—Anorexia—Dexamethasone—psoriasis	3.19e-05	0.000117	CcSEcCtD
Bortezomib—Urticaria—Prednisolone—psoriasis	3.19e-05	0.000117	CcSEcCtD
Bortezomib—Cardiac disorder—Methotrexate—psoriasis	3.18e-05	0.000117	CcSEcCtD
Bortezomib—Fatigue—Triamcinolone—psoriasis	3.18e-05	0.000117	CcSEcCtD
Bortezomib—PSMB8—Betamethasone—Hydrocortisone—psoriasis	3.17e-05	0.00557	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Hydrocortisone—psoriasis	3.17e-05	0.00557	CbGdCrCtD
Bortezomib—Hypersensitivity—Mycophenolate mofetil—psoriasis	3.17e-05	0.000117	CcSEcCtD
Bortezomib—Asthenia—Cyclosporine—psoriasis	3.16e-05	0.000116	CcSEcCtD
Bortezomib—Pain—Triamcinolone—psoriasis	3.16e-05	0.000116	CcSEcCtD
Bortezomib—Loss of consciousness—Prednisone—psoriasis	3.14e-05	0.000116	CcSEcCtD
Bortezomib—Hypotension—Betamethasone—psoriasis	3.13e-05	0.000115	CcSEcCtD
Bortezomib—Hypotension—Dexamethasone—psoriasis	3.13e-05	0.000115	CcSEcCtD
Bortezomib—Pruritus—Cyclosporine—psoriasis	3.12e-05	0.000115	CcSEcCtD
Bortezomib—Urticaria—Hydrocortisone—psoriasis	3.11e-05	0.000115	CcSEcCtD
Bortezomib—Angiopathy—Methotrexate—psoriasis	3.11e-05	0.000115	CcSEcCtD
Bortezomib—Immune system disorder—Methotrexate—psoriasis	3.1e-05	0.000114	CcSEcCtD
Bortezomib—Abdominal pain—Hydrocortisone—psoriasis	3.1e-05	0.000114	CcSEcCtD
Bortezomib—Body temperature increased—Hydrocortisone—psoriasis	3.1e-05	0.000114	CcSEcCtD
Bortezomib—Convulsion—Prednisone—psoriasis	3.1e-05	0.000114	CcSEcCtD
Bortezomib—Mediastinal disorder—Methotrexate—psoriasis	3.09e-05	0.000114	CcSEcCtD
Bortezomib—Asthenia—Mycophenolate mofetil—psoriasis	3.09e-05	0.000114	CcSEcCtD
Bortezomib—Hypertension—Prednisone—psoriasis	3.08e-05	0.000114	CcSEcCtD
Bortezomib—Chills—Methotrexate—psoriasis	3.08e-05	0.000113	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Dexamethasone—psoriasis	3.05e-05	0.000112	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Betamethasone—psoriasis	3.05e-05	0.000112	CcSEcCtD
Bortezomib—Pruritus—Mycophenolate mofetil—psoriasis	3.04e-05	0.000112	CcSEcCtD
Bortezomib—Arthralgia—Prednisone—psoriasis	3.04e-05	0.000112	CcSEcCtD
Bortezomib—Myalgia—Prednisone—psoriasis	3.04e-05	0.000112	CcSEcCtD
Bortezomib—Feeling abnormal—Triamcinolone—psoriasis	3.04e-05	0.000112	CcSEcCtD
Bortezomib—Anxiety—Prednisone—psoriasis	3.03e-05	0.000112	CcSEcCtD
Bortezomib—Insomnia—Betamethasone—psoriasis	3.03e-05	0.000111	CcSEcCtD
Bortezomib—Insomnia—Dexamethasone—psoriasis	3.03e-05	0.000111	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	3.02e-05	0.000111	CcSEcCtD
Bortezomib—Diarrhoea—Cyclosporine—psoriasis	3.02e-05	0.000111	CcSEcCtD
Bortezomib—Paraesthesia—Betamethasone—psoriasis	3.01e-05	0.000111	CcSEcCtD
Bortezomib—Paraesthesia—Dexamethasone—psoriasis	3.01e-05	0.000111	CcSEcCtD
Bortezomib—Discomfort—Prednisone—psoriasis	3.01e-05	0.000111	CcSEcCtD
Bortezomib—Mental disorder—Methotrexate—psoriasis	3.01e-05	0.000111	CcSEcCtD
Bortezomib—Erythema—Methotrexate—psoriasis	2.99e-05	0.00011	CcSEcCtD
Bortezomib—Malnutrition—Methotrexate—psoriasis	2.99e-05	0.00011	CcSEcCtD
Bortezomib—Hypersensitivity—Prednisolone—psoriasis	2.96e-05	0.000109	CcSEcCtD
Bortezomib—Dyspepsia—Betamethasone—psoriasis	2.95e-05	0.000108	CcSEcCtD
Bortezomib—Dyspepsia—Dexamethasone—psoriasis	2.95e-05	0.000108	CcSEcCtD
Bortezomib—PSMB8—Betamethasone—Dexamethasone—psoriasis	2.95e-05	0.00517	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Betamethasone—psoriasis	2.95e-05	0.00517	CbGdCrCtD
Bortezomib—Diarrhoea—Mycophenolate mofetil—psoriasis	2.94e-05	0.000108	CcSEcCtD
Bortezomib—Urticaria—Triamcinolone—psoriasis	2.93e-05	0.000108	CcSEcCtD
Bortezomib—Dysgeusia—Methotrexate—psoriasis	2.92e-05	0.000108	CcSEcCtD
Bortezomib—Body temperature increased—Triamcinolone—psoriasis	2.92e-05	0.000107	CcSEcCtD
Bortezomib—Dizziness—Cyclosporine—psoriasis	2.92e-05	0.000107	CcSEcCtD
Bortezomib—Anaphylactic shock—Prednisone—psoriasis	2.92e-05	0.000107	CcSEcCtD
Bortezomib—Oedema—Prednisone—psoriasis	2.92e-05	0.000107	CcSEcCtD
Bortezomib—Decreased appetite—Dexamethasone—psoriasis	2.91e-05	0.000107	CcSEcCtD
Bortezomib—Decreased appetite—Betamethasone—psoriasis	2.91e-05	0.000107	CcSEcCtD
Bortezomib—Infection—Prednisone—psoriasis	2.9e-05	0.000107	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Betamethasone—psoriasis	2.89e-05	0.000106	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Dexamethasone—psoriasis	2.89e-05	0.000106	CcSEcCtD
Bortezomib—Back pain—Methotrexate—psoriasis	2.89e-05	0.000106	CcSEcCtD
Bortezomib—Hypersensitivity—Hydrocortisone—psoriasis	2.89e-05	0.000106	CcSEcCtD
Bortezomib—Fatigue—Betamethasone—psoriasis	2.89e-05	0.000106	CcSEcCtD
Bortezomib—Fatigue—Dexamethasone—psoriasis	2.89e-05	0.000106	CcSEcCtD
Bortezomib—PSMB8—Betamethasone—Triamcinolone—psoriasis	2.88e-05	0.00505	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Triamcinolone—psoriasis	2.88e-05	0.00505	CbGdCrCtD
Bortezomib—Shock—Prednisone—psoriasis	2.87e-05	0.000106	CcSEcCtD
Bortezomib—Pain—Betamethasone—psoriasis	2.86e-05	0.000105	CcSEcCtD
Bortezomib—Pain—Dexamethasone—psoriasis	2.86e-05	0.000105	CcSEcCtD
Bortezomib—Nervous system disorder—Prednisone—psoriasis	2.86e-05	0.000105	CcSEcCtD
Bortezomib—Tachycardia—Prednisone—psoriasis	2.85e-05	0.000105	CcSEcCtD
Bortezomib—Dizziness—Mycophenolate mofetil—psoriasis	2.84e-05	0.000105	CcSEcCtD
Bortezomib—Skin disorder—Prednisone—psoriasis	2.83e-05	0.000104	CcSEcCtD
Bortezomib—Hyperhidrosis—Prednisone—psoriasis	2.82e-05	0.000104	CcSEcCtD
Bortezomib—Vision blurred—Methotrexate—psoriasis	2.81e-05	0.000104	CcSEcCtD
Bortezomib—Asthenia—Hydrocortisone—psoriasis	2.81e-05	0.000104	CcSEcCtD
Bortezomib—Vomiting—Cyclosporine—psoriasis	2.8e-05	0.000103	CcSEcCtD
Bortezomib—Rash—Cyclosporine—psoriasis	2.78e-05	0.000102	CcSEcCtD
Bortezomib—Anorexia—Prednisone—psoriasis	2.78e-05	0.000102	CcSEcCtD
Bortezomib—Dermatitis—Cyclosporine—psoriasis	2.78e-05	0.000102	CcSEcCtD
Bortezomib—Pruritus—Hydrocortisone—psoriasis	2.77e-05	0.000102	CcSEcCtD
Bortezomib—Ill-defined disorder—Methotrexate—psoriasis	2.77e-05	0.000102	CcSEcCtD
Bortezomib—Headache—Cyclosporine—psoriasis	2.76e-05	0.000102	CcSEcCtD
Bortezomib—Anaemia—Methotrexate—psoriasis	2.76e-05	0.000102	CcSEcCtD
Bortezomib—Feeling abnormal—Dexamethasone—psoriasis	2.76e-05	0.000102	CcSEcCtD
Bortezomib—Feeling abnormal—Betamethasone—psoriasis	2.76e-05	0.000102	CcSEcCtD
Bortezomib—Gastrointestinal pain—Betamethasone—psoriasis	2.74e-05	0.000101	CcSEcCtD
Bortezomib—Gastrointestinal pain—Dexamethasone—psoriasis	2.74e-05	0.000101	CcSEcCtD
Bortezomib—Vomiting—Mycophenolate mofetil—psoriasis	2.74e-05	0.000101	CcSEcCtD
Bortezomib—PSMB8—Betamethasone—Prednisone—psoriasis	2.73e-05	0.00479	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Prednisone—psoriasis	2.73e-05	0.00479	CbGdCrCtD
Bortezomib—Hypersensitivity—Triamcinolone—psoriasis	2.72e-05	0.0001	CcSEcCtD
Bortezomib—Rash—Mycophenolate mofetil—psoriasis	2.71e-05	9.98e-05	CcSEcCtD
Bortezomib—Dermatitis—Mycophenolate mofetil—psoriasis	2.71e-05	9.98e-05	CcSEcCtD
Bortezomib—Headache—Mycophenolate mofetil—psoriasis	2.69e-05	9.92e-05	CcSEcCtD
Bortezomib—Malaise—Methotrexate—psoriasis	2.69e-05	9.91e-05	CcSEcCtD
Bortezomib—Vertigo—Methotrexate—psoriasis	2.68e-05	9.88e-05	CcSEcCtD
Bortezomib—Diarrhoea—Hydrocortisone—psoriasis	2.68e-05	9.87e-05	CcSEcCtD
Bortezomib—Leukopenia—Methotrexate—psoriasis	2.67e-05	9.84e-05	CcSEcCtD
Bortezomib—PSMB8—Betamethasone—Prednisolone—psoriasis	2.67e-05	0.00468	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Prednisolone—psoriasis	2.67e-05	0.00468	CbGdCrCtD
Bortezomib—Urticaria—Betamethasone—psoriasis	2.66e-05	9.79e-05	CcSEcCtD
Bortezomib—Urticaria—Dexamethasone—psoriasis	2.66e-05	9.79e-05	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Prednisone—psoriasis	2.66e-05	9.78e-05	CcSEcCtD
Bortezomib—Dizziness—Prednisolone—psoriasis	2.65e-05	9.77e-05	CcSEcCtD
Bortezomib—Asthenia—Triamcinolone—psoriasis	2.65e-05	9.75e-05	CcSEcCtD
Bortezomib—Abdominal pain—Dexamethasone—psoriasis	2.65e-05	9.74e-05	CcSEcCtD
Bortezomib—Abdominal pain—Betamethasone—psoriasis	2.65e-05	9.74e-05	CcSEcCtD
Bortezomib—Body temperature increased—Dexamethasone—psoriasis	2.65e-05	9.74e-05	CcSEcCtD
Bortezomib—Body temperature increased—Betamethasone—psoriasis	2.65e-05	9.74e-05	CcSEcCtD
Bortezomib—Insomnia—Prednisone—psoriasis	2.64e-05	9.71e-05	CcSEcCtD
Bortezomib—Nausea—Cyclosporine—psoriasis	2.62e-05	9.64e-05	CcSEcCtD
Bortezomib—Paraesthesia—Prednisone—psoriasis	2.62e-05	9.64e-05	CcSEcCtD
Bortezomib—Pruritus—Triamcinolone—psoriasis	2.61e-05	9.61e-05	CcSEcCtD
Bortezomib—Cough—Methotrexate—psoriasis	2.61e-05	9.59e-05	CcSEcCtD
Bortezomib—Dizziness—Hydrocortisone—psoriasis	2.59e-05	9.54e-05	CcSEcCtD
Bortezomib—Convulsion—Methotrexate—psoriasis	2.59e-05	9.52e-05	CcSEcCtD
Bortezomib—Dyspepsia—Prednisone—psoriasis	2.57e-05	9.45e-05	CcSEcCtD
Bortezomib—Nausea—Mycophenolate mofetil—psoriasis	2.56e-05	9.41e-05	CcSEcCtD
Bortezomib—Chest pain—Methotrexate—psoriasis	2.54e-05	9.36e-05	CcSEcCtD
Bortezomib—Myalgia—Methotrexate—psoriasis	2.54e-05	9.36e-05	CcSEcCtD
Bortezomib—Arthralgia—Methotrexate—psoriasis	2.54e-05	9.36e-05	CcSEcCtD
Bortezomib—Decreased appetite—Prednisone—psoriasis	2.53e-05	9.33e-05	CcSEcCtD
Bortezomib—Rash—Prednisolone—psoriasis	2.53e-05	9.31e-05	CcSEcCtD
Bortezomib—Dermatitis—Prednisolone—psoriasis	2.53e-05	9.3e-05	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	2.52e-05	9.29e-05	CcSEcCtD
Bortezomib—Fatigue—Prednisone—psoriasis	2.51e-05	9.25e-05	CcSEcCtD
Bortezomib—Headache—Prednisolone—psoriasis	2.51e-05	9.25e-05	CcSEcCtD
Bortezomib—Discomfort—Methotrexate—psoriasis	2.51e-05	9.25e-05	CcSEcCtD
Bortezomib—Constipation—Prednisone—psoriasis	2.49e-05	9.18e-05	CcSEcCtD
Bortezomib—Vomiting—Hydrocortisone—psoriasis	2.49e-05	9.17e-05	CcSEcCtD
Bortezomib—Rash—Hydrocortisone—psoriasis	2.47e-05	9.1e-05	CcSEcCtD
Bortezomib—Dermatitis—Hydrocortisone—psoriasis	2.47e-05	9.09e-05	CcSEcCtD
Bortezomib—Confusional state—Methotrexate—psoriasis	2.46e-05	9.05e-05	CcSEcCtD
Bortezomib—Headache—Hydrocortisone—psoriasis	2.46e-05	9.04e-05	CcSEcCtD
Bortezomib—Dizziness—Triamcinolone—psoriasis	2.44e-05	8.98e-05	CcSEcCtD
Bortezomib—Anaphylactic shock—Methotrexate—psoriasis	2.44e-05	8.97e-05	CcSEcCtD
Bortezomib—Infection—Methotrexate—psoriasis	2.42e-05	8.91e-05	CcSEcCtD
Bortezomib—Feeling abnormal—Prednisone—psoriasis	2.4e-05	8.85e-05	CcSEcCtD
Bortezomib—Asthenia—Dexamethasone—psoriasis	2.4e-05	8.84e-05	CcSEcCtD
Bortezomib—Asthenia—Betamethasone—psoriasis	2.4e-05	8.84e-05	CcSEcCtD
Bortezomib—Nervous system disorder—Methotrexate—psoriasis	2.39e-05	8.8e-05	CcSEcCtD
Bortezomib—Thrombocytopenia—Methotrexate—psoriasis	2.39e-05	8.78e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Prednisone—psoriasis	2.38e-05	8.78e-05	CcSEcCtD
Bortezomib—Nausea—Prednisolone—psoriasis	2.38e-05	8.77e-05	CcSEcCtD
Bortezomib—Pruritus—Betamethasone—psoriasis	2.37e-05	8.72e-05	CcSEcCtD
Bortezomib—Pruritus—Dexamethasone—psoriasis	2.37e-05	8.72e-05	CcSEcCtD
Bortezomib—Skin disorder—Methotrexate—psoriasis	2.37e-05	8.71e-05	CcSEcCtD
Bortezomib—Hyperhidrosis—Methotrexate—psoriasis	2.36e-05	8.67e-05	CcSEcCtD
Bortezomib—Vomiting—Triamcinolone—psoriasis	2.35e-05	8.64e-05	CcSEcCtD
Bortezomib—Nausea—Hydrocortisone—psoriasis	2.33e-05	8.57e-05	CcSEcCtD
Bortezomib—Rash—Triamcinolone—psoriasis	2.33e-05	8.56e-05	CcSEcCtD
Bortezomib—Dermatitis—Triamcinolone—psoriasis	2.32e-05	8.56e-05	CcSEcCtD
Bortezomib—Anorexia—Methotrexate—psoriasis	2.32e-05	8.55e-05	CcSEcCtD
Bortezomib—Urticaria—Prednisone—psoriasis	2.32e-05	8.53e-05	CcSEcCtD
Bortezomib—Headache—Triamcinolone—psoriasis	2.31e-05	8.51e-05	CcSEcCtD
Bortezomib—Body temperature increased—Prednisone—psoriasis	2.31e-05	8.49e-05	CcSEcCtD
Bortezomib—Abdominal pain—Prednisone—psoriasis	2.31e-05	8.49e-05	CcSEcCtD
Bortezomib—Diarrhoea—Betamethasone—psoriasis	2.29e-05	8.43e-05	CcSEcCtD
Bortezomib—Diarrhoea—Dexamethasone—psoriasis	2.29e-05	8.43e-05	CcSEcCtD
Bortezomib—Hypotension—Methotrexate—psoriasis	2.28e-05	8.38e-05	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Methotrexate—psoriasis	2.22e-05	8.17e-05	CcSEcCtD
Bortezomib—Dizziness—Dexamethasone—psoriasis	2.21e-05	8.15e-05	CcSEcCtD
Bortezomib—Dizziness—Betamethasone—psoriasis	2.21e-05	8.15e-05	CcSEcCtD
Bortezomib—Insomnia—Methotrexate—psoriasis	2.2e-05	8.11e-05	CcSEcCtD
Bortezomib—Nausea—Triamcinolone—psoriasis	2.19e-05	8.07e-05	CcSEcCtD
Bortezomib—Paraesthesia—Methotrexate—psoriasis	2.19e-05	8.06e-05	CcSEcCtD
Bortezomib—Dyspnoea—Methotrexate—psoriasis	2.17e-05	8e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Prednisone—psoriasis	2.15e-05	7.91e-05	CcSEcCtD
Bortezomib—Dyspepsia—Methotrexate—psoriasis	2.15e-05	7.9e-05	CcSEcCtD
Bortezomib—Vomiting—Dexamethasone—psoriasis	2.13e-05	7.84e-05	CcSEcCtD
Bortezomib—Vomiting—Betamethasone—psoriasis	2.13e-05	7.84e-05	CcSEcCtD
Bortezomib—Decreased appetite—Methotrexate—psoriasis	2.12e-05	7.8e-05	CcSEcCtD
Bortezomib—Rash—Betamethasone—psoriasis	2.11e-05	7.77e-05	CcSEcCtD
Bortezomib—Rash—Dexamethasone—psoriasis	2.11e-05	7.77e-05	CcSEcCtD
Bortezomib—Dermatitis—Dexamethasone—psoriasis	2.11e-05	7.76e-05	CcSEcCtD
Bortezomib—Dermatitis—Betamethasone—psoriasis	2.11e-05	7.76e-05	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Methotrexate—psoriasis	2.1e-05	7.74e-05	CcSEcCtD
Bortezomib—Fatigue—Methotrexate—psoriasis	2.1e-05	7.73e-05	CcSEcCtD
Bortezomib—Headache—Betamethasone—psoriasis	2.1e-05	7.72e-05	CcSEcCtD
Bortezomib—Headache—Dexamethasone—psoriasis	2.1e-05	7.72e-05	CcSEcCtD
Bortezomib—Asthenia—Prednisone—psoriasis	2.09e-05	7.7e-05	CcSEcCtD
Bortezomib—Pain—Methotrexate—psoriasis	2.08e-05	7.67e-05	CcSEcCtD
Bortezomib—Pruritus—Prednisone—psoriasis	2.06e-05	7.59e-05	CcSEcCtD
Bortezomib—Feeling abnormal—Methotrexate—psoriasis	2.01e-05	7.39e-05	CcSEcCtD
Bortezomib—Diarrhoea—Prednisone—psoriasis	2e-05	7.34e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Methotrexate—psoriasis	1.99e-05	7.34e-05	CcSEcCtD
Bortezomib—Nausea—Dexamethasone—psoriasis	1.99e-05	7.32e-05	CcSEcCtD
Bortezomib—Nausea—Betamethasone—psoriasis	1.99e-05	7.32e-05	CcSEcCtD
Bortezomib—PSMB5—Immune System—HLA-DRB1—psoriasis	1.94e-05	0.000122	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—HLA-DRB1—psoriasis	1.94e-05	0.000122	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HLA-DRB1—psoriasis	1.94e-05	0.000122	CbGpPWpGaD
Bortezomib—Urticaria—Methotrexate—psoriasis	1.94e-05	7.13e-05	CcSEcCtD
Bortezomib—PSMB8—Disease—HLA-A—psoriasis	1.93e-05	0.000122	CbGpPWpGaD
Bortezomib—Dizziness—Prednisone—psoriasis	1.93e-05	7.1e-05	CcSEcCtD
Bortezomib—Abdominal pain—Methotrexate—psoriasis	1.93e-05	7.09e-05	CcSEcCtD
Bortezomib—Body temperature increased—Methotrexate—psoriasis	1.93e-05	7.09e-05	CcSEcCtD
Bortezomib—PSMA1—Cell Cycle—TP53—psoriasis	1.92e-05	0.000121	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—NFKB1—psoriasis	1.92e-05	0.000121	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—HLA-DRB1—psoriasis	1.91e-05	0.000121	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle—TP53—psoriasis	1.91e-05	0.000121	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle—TP53—psoriasis	1.9e-05	0.00012	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—IFNG—psoriasis	1.87e-05	0.000118	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—ICAM1—psoriasis	1.86e-05	0.000117	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—ICAM1—psoriasis	1.86e-05	0.000117	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—ICAM1—psoriasis	1.86e-05	0.000117	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—IFNG—psoriasis	1.86e-05	0.000117	CbGpPWpGaD
Bortezomib—Vomiting—Prednisone—psoriasis	1.85e-05	6.82e-05	CcSEcCtD
Bortezomib—PSMD2—Immune System—IFNG—psoriasis	1.85e-05	0.000117	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—NFKBIA—psoriasis	1.85e-05	0.000117	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—NFKBIA—psoriasis	1.85e-05	0.000117	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—NFKBIA—psoriasis	1.85e-05	0.000117	CbGpPWpGaD
Bortezomib—PSMA1—Disease—TYK2—psoriasis	1.84e-05	0.000116	CbGpPWpGaD
Bortezomib—Rash—Prednisone—psoriasis	1.84e-05	6.77e-05	CcSEcCtD
Bortezomib—Dermatitis—Prednisone—psoriasis	1.84e-05	6.76e-05	CcSEcCtD
Bortezomib—PSMB8—Immune System—ICAM1—psoriasis	1.83e-05	0.000116	CbGpPWpGaD
Bortezomib—PSMD1—Disease—TYK2—psoriasis	1.83e-05	0.000116	CbGpPWpGaD
Bortezomib—PSMB2—Disease—APOE—psoriasis	1.83e-05	0.000115	CbGpPWpGaD
Bortezomib—PSMB1—Disease—APOE—psoriasis	1.83e-05	0.000115	CbGpPWpGaD
Bortezomib—PSMB5—Disease—APOE—psoriasis	1.83e-05	0.000115	CbGpPWpGaD
Bortezomib—Headache—Prednisone—psoriasis	1.83e-05	6.72e-05	CcSEcCtD
Bortezomib—PSMD2—Disease—TYK2—psoriasis	1.82e-05	0.000115	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—NFKBIA—psoriasis	1.82e-05	0.000115	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP2S1—psoriasis	1.82e-05	0.000115	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NDUFA5—psoriasis	1.81e-05	0.000114	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—CD4—psoriasis	1.8e-05	0.000114	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP2S1—psoriasis	1.8e-05	0.000114	CbGpPWpGaD
Bortezomib—PSMB8—Disease—APOE—psoriasis	1.8e-05	0.000114	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.8e-05	0.000114	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CD4—psoriasis	1.8e-05	0.000113	CbGpPWpGaD
Bortezomib—Hypersensitivity—Methotrexate—psoriasis	1.8e-05	6.61e-05	CcSEcCtD
Bortezomib—PSMD2—Immune System—CD4—psoriasis	1.79e-05	0.000113	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—PPARG—psoriasis	1.76e-05	0.000111	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—PPARG—psoriasis	1.75e-05	0.000111	CbGpPWpGaD
Bortezomib—Asthenia—Methotrexate—psoriasis	1.75e-05	6.44e-05	CcSEcCtD
Bortezomib—PSMD2—Metabolism—PPARG—psoriasis	1.74e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—SOCS1—psoriasis	1.74e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—SOCS1—psoriasis	1.74e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—SOCS1—psoriasis	1.74e-05	0.00011	CbGpPWpGaD
Bortezomib—Nausea—Prednisone—psoriasis	1.73e-05	6.38e-05	CcSEcCtD
Bortezomib—Pruritus—Methotrexate—psoriasis	1.72e-05	6.35e-05	CcSEcCtD
Bortezomib—PSMB5—Gene Expression—PPARG—psoriasis	1.72e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—PPARG—psoriasis	1.72e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—PPARG—psoriasis	1.72e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—SOCS1—psoriasis	1.71e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMB5—Disease—NOS2—psoriasis	1.7e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMB2—Disease—NOS2—psoriasis	1.7e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMB1—Disease—NOS2—psoriasis	1.7e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—PPARG—psoriasis	1.69e-05	0.000107	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.69e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—LEP—psoriasis	1.69e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—APOE—psoriasis	1.69e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—LEP—psoriasis	1.68e-05	0.000106	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—APOE—psoriasis	1.68e-05	0.000106	CbGpPWpGaD
Bortezomib—PSMB8—Disease—NOS2—psoriasis	1.68e-05	0.000106	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CARM1—psoriasis	1.68e-05	0.000106	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—APOE—psoriasis	1.67e-05	0.000106	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—LEP—psoriasis	1.67e-05	0.000106	CbGpPWpGaD
Bortezomib—Diarrhoea—Methotrexate—psoriasis	1.67e-05	6.14e-05	CcSEcCtD
Bortezomib—PSMA1—Disease—CD4—psoriasis	1.67e-05	0.000105	CbGpPWpGaD
Bortezomib—PSMD1—Disease—CD4—psoriasis	1.66e-05	0.000105	CbGpPWpGaD
Bortezomib—PSMD2—Disease—CD4—psoriasis	1.65e-05	0.000104	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—JUN—psoriasis	1.62e-05	0.000102	CbGpPWpGaD
Bortezomib—Dizziness—Methotrexate—psoriasis	1.61e-05	5.93e-05	CcSEcCtD
Bortezomib—PSMD1—Immune System—JUN—psoriasis	1.61e-05	0.000101	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—JUN—psoriasis	1.6e-05	0.000101	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—NFKBIA—psoriasis	1.58e-05	9.94e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—NFKBIA—psoriasis	1.57e-05	9.89e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.57e-05	9.89e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—NFKBIA—psoriasis	1.56e-05	9.85e-05	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—NFKB1—psoriasis	1.55e-05	9.81e-05	CbGpPWpGaD
Bortezomib—Vomiting—Methotrexate—psoriasis	1.55e-05	5.7e-05	CcSEcCtD
Bortezomib—PSMD1—Immune System—NFKB1—psoriasis	1.55e-05	9.77e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP2S1—psoriasis	1.54e-05	9.73e-05	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—NFKB1—psoriasis	1.54e-05	9.72e-05	CbGpPWpGaD
Bortezomib—Rash—Methotrexate—psoriasis	1.54e-05	5.66e-05	CcSEcCtD
Bortezomib—Dermatitis—Methotrexate—psoriasis	1.54e-05	5.65e-05	CcSEcCtD
Bortezomib—PSMB5—Metabolism—APOE—psoriasis	1.53e-05	9.67e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—APOE—psoriasis	1.53e-05	9.67e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—APOE—psoriasis	1.53e-05	9.67e-05	CbGpPWpGaD
Bortezomib—Headache—Methotrexate—psoriasis	1.53e-05	5.62e-05	CcSEcCtD
Bortezomib—PSMB5—Immune System—TYK2—psoriasis	1.51e-05	9.54e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—TYK2—psoriasis	1.51e-05	9.54e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—TYK2—psoriasis	1.51e-05	9.54e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—APOE—psoriasis	1.51e-05	9.53e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—TYK2—psoriasis	1.49e-05	9.41e-05	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—TP53—psoriasis	1.45e-05	9.18e-05	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—TP53—psoriasis	1.45e-05	9.18e-05	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—TP53—psoriasis	1.45e-05	9.18e-05	CbGpPWpGaD
Bortezomib—Nausea—Methotrexate—psoriasis	1.45e-05	5.33e-05	CcSEcCtD
Bortezomib—PSMB8—Cell Cycle—TP53—psoriasis	1.43e-05	9.05e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IFNG—psoriasis	1.42e-05	8.94e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IFNG—psoriasis	1.42e-05	8.94e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IFNG—psoriasis	1.42e-05	8.94e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NDUFA5—psoriasis	1.4e-05	8.83e-05	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—STAT3—psoriasis	1.4e-05	8.82e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—TYK2—psoriasis	1.4e-05	8.81e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—TYK2—psoriasis	1.4e-05	8.81e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—TYK2—psoriasis	1.4e-05	8.81e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IFNG—psoriasis	1.4e-05	8.81e-05	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—STAT3—psoriasis	1.39e-05	8.78e-05	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—STAT3—psoriasis	1.38e-05	8.73e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—TYK2—psoriasis	1.38e-05	8.69e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CD4—psoriasis	1.37e-05	8.63e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CD4—psoriasis	1.37e-05	8.63e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CD4—psoriasis	1.37e-05	8.63e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CD4—psoriasis	1.35e-05	8.51e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PPARG—psoriasis	1.33e-05	8.42e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PPARG—psoriasis	1.33e-05	8.42e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PPARG—psoriasis	1.33e-05	8.42e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PPARG—psoriasis	1.32e-05	8.3e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TYK2—psoriasis	1.29e-05	8.14e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—STAT3—psoriasis	1.29e-05	8.14e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TYK2—psoriasis	1.28e-05	8.1e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—STAT3—psoriasis	1.28e-05	8.1e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—LEP—psoriasis	1.28e-05	8.08e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—LEP—psoriasis	1.28e-05	8.08e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—APOE—psoriasis	1.28e-05	8.08e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—APOE—psoriasis	1.28e-05	8.08e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—APOE—psoriasis	1.28e-05	8.08e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—LEP—psoriasis	1.28e-05	8.08e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TYK2—psoriasis	1.28e-05	8.06e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—STAT3—psoriasis	1.28e-05	8.06e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.27e-05	8e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—LEP—psoriasis	1.26e-05	7.97e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—APOE—psoriasis	1.26e-05	7.97e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—CD4—psoriasis	1.26e-05	7.97e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—CD4—psoriasis	1.26e-05	7.97e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—CD4—psoriasis	1.26e-05	7.97e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—CD4—psoriasis	1.24e-05	7.86e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—JUN—psoriasis	1.22e-05	7.73e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—JUN—psoriasis	1.22e-05	7.73e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—JUN—psoriasis	1.22e-05	7.73e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—JUN—psoriasis	1.21e-05	7.62e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NFKBIA—psoriasis	1.19e-05	7.53e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NFKBIA—psoriasis	1.19e-05	7.53e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NFKBIA—psoriasis	1.19e-05	7.53e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP2S1—psoriasis	1.19e-05	7.51e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CARM1—psoriasis	1.18e-05	7.45e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—NFKB1—psoriasis	1.18e-05	7.44e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—NFKB1—psoriasis	1.18e-05	7.44e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—NFKB1—psoriasis	1.18e-05	7.44e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NFKBIA—psoriasis	1.18e-05	7.43e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—NFKB1—psoriasis	1.16e-05	7.33e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.16e-05	7.33e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CXCL8—psoriasis	1.12e-05	7.09e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CXCL8—psoriasis	1.12e-05	7.06e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CXCL8—psoriasis	1.11e-05	7.02e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.1e-05	6.97e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CARM1—psoriasis	1.08e-05	6.83e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—STAT3—psoriasis	1.06e-05	6.68e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—STAT3—psoriasis	1.06e-05	6.68e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—STAT3—psoriasis	1.06e-05	6.68e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—JUN—psoriasis	1.04e-05	6.59e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—STAT3—psoriasis	1.04e-05	6.59e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—JUN—psoriasis	1.04e-05	6.56e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.04e-05	6.54e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—JUN—psoriasis	1.03e-05	6.53e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CAT—psoriasis	1.03e-05	6.51e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.01e-05	6.39e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—NFKB1—psoriasis	1.01e-05	6.34e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—NFKB1—psoriasis	1e-05	6.31e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—NFKB1—psoriasis	9.96e-06	6.28e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TYK2—psoriasis	9.78e-06	6.17e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TYK2—psoriasis	9.78e-06	6.17e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TYK2—psoriasis	9.78e-06	6.17e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—STAT3—psoriasis	9.78e-06	6.17e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—STAT3—psoriasis	9.78e-06	6.17e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—STAT3—psoriasis	9.78e-06	6.17e-05	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—IL6—psoriasis	9.76e-06	6.16e-05	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—IL6—psoriasis	9.71e-06	6.13e-05	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IL6—psoriasis	9.67e-06	6.1e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CARM1—psoriasis	9.66e-06	6.1e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TYK2—psoriasis	9.64e-06	6.08e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—STAT3—psoriasis	9.64e-06	6.08e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.45e-06	5.97e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—VEGFA—psoriasis	9.12e-06	5.76e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—VEGFA—psoriasis	9.08e-06	5.73e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—VEGFA—psoriasis	9.04e-06	5.7e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—STAT3—psoriasis	9.03e-06	5.7e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.03e-06	5.7e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—IL6—psoriasis	9.01e-06	5.69e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—STAT3—psoriasis	8.99e-06	5.67e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—IL6—psoriasis	8.97e-06	5.66e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—STAT3—psoriasis	8.95e-06	5.65e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—IL6—psoriasis	8.93e-06	5.63e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CARM1—psoriasis	8.89e-06	5.61e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CARM1—psoriasis	8.81e-06	5.56e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CXCL8—psoriasis	8.51e-06	5.37e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CXCL8—psoriasis	8.51e-06	5.37e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CXCL8—psoriasis	8.51e-06	5.37e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CXCL8—psoriasis	8.39e-06	5.3e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.24e-06	5.2e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.08e-06	5.1e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—APOE—psoriasis	8.01e-06	5.05e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—JUN—psoriasis	7.91e-06	4.99e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—JUN—psoriasis	7.91e-06	4.99e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—JUN—psoriasis	7.91e-06	4.99e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—JUN—psoriasis	7.8e-06	4.92e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NFKB1—psoriasis	7.62e-06	4.81e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NFKB1—psoriasis	7.62e-06	4.81e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NFKB1—psoriasis	7.62e-06	4.81e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CARM1—psoriasis	7.53e-06	4.75e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NFKB1—psoriasis	7.51e-06	4.74e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL6—psoriasis	7.4e-06	4.67e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL6—psoriasis	7.4e-06	4.67e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL6—psoriasis	7.4e-06	4.67e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL6—psoriasis	7.29e-06	4.6e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CAT—psoriasis	7.26e-06	4.58e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.04e-06	4.44e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PPARG—psoriasis	6.98e-06	4.4e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—VEGFA—psoriasis	6.91e-06	4.36e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—VEGFA—psoriasis	6.91e-06	4.36e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—VEGFA—psoriasis	6.91e-06	4.36e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—psoriasis	6.89e-06	4.35e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—psoriasis	6.86e-06	4.33e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—STAT3—psoriasis	6.85e-06	4.32e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—STAT3—psoriasis	6.85e-06	4.32e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—STAT3—psoriasis	6.85e-06	4.32e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—IL6—psoriasis	6.83e-06	4.31e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—IL6—psoriasis	6.83e-06	4.31e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—IL6—psoriasis	6.83e-06	4.31e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—psoriasis	6.83e-06	4.31e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—VEGFA—psoriasis	6.82e-06	4.3e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—STAT3—psoriasis	6.75e-06	4.26e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—IL6—psoriasis	6.73e-06	4.25e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CAT—psoriasis	6.66e-06	4.2e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL6—psoriasis	6.31e-06	3.98e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL6—psoriasis	6.28e-06	3.96e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL6—psoriasis	6.25e-06	3.94e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CAT—psoriasis	5.94e-06	3.75e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CARM1—psoriasis	5.81e-06	3.67e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—APOE—psoriasis	5.64e-06	3.56e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CAT—psoriasis	5.47e-06	3.45e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CAT—psoriasis	5.42e-06	3.42e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—psoriasis	5.22e-06	3.3e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—psoriasis	5.22e-06	3.3e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—psoriasis	5.22e-06	3.3e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—APOE—psoriasis	5.17e-06	3.27e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—psoriasis	5.15e-06	3.25e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPARG—psoriasis	4.92e-06	3.1e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6—psoriasis	4.78e-06	3.02e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6—psoriasis	4.78e-06	3.02e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6—psoriasis	4.78e-06	3.02e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6—psoriasis	4.71e-06	2.98e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CAT—psoriasis	4.63e-06	2.92e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—APOE—psoriasis	4.62e-06	2.91e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARG—psoriasis	4.51e-06	2.84e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APOE—psoriasis	4.25e-06	2.68e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APOE—psoriasis	4.21e-06	2.66e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARG—psoriasis	4.02e-06	2.54e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARG—psoriasis	3.7e-06	2.33e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARG—psoriasis	3.67e-06	2.31e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOE—psoriasis	3.6e-06	2.27e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CAT—psoriasis	3.57e-06	2.26e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARG—psoriasis	3.13e-06	1.98e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOE—psoriasis	2.78e-06	1.75e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARG—psoriasis	2.42e-06	1.53e-05	CbGpPWpGaD
